Business Standard

Bharat Biotech's Covaxin shows over 77% efficacy in phase 3 trials

The vaccine has shown an efficacy rate of 93 per cent against severe disease and 60 per cent against asymptomatic Covid-19

Covaxin, bharat biotech, coronavirus vaccine
Premium

Now that the data from phase 3 trials has been reviewed by the drug regulator of the country of origin, the firm can present it before the World Health Organization

Sohini Das Mumbai
Bharat Biotech’s Covaxin, India’s first indigenous vaccine against Covid-19, has shown 77.6 per cent efficacy in the final analysis of phase 3 clinical trials, according to sources in the expert panel that reviewed the data.

The vaccine has shown an efficacy rate of 93 per cent against severe disease and 60 per cent against asymptomatic Covid-19.

The Hyderabad-based vaccine manufacturer sought a full marketing authorisation for Covaxin after presenting the final analysis of phase 3 data before the Subject Expert Committee (SEC), which is advising the Drugs Controller General of India (DCGI), a source said.

“A full marketing authorisation has not yet been

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 23 2021 | 12:42 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com